BioInnovation Institute is providing additional €7.8 million funding to six companies to advance technologies across healthcare, agriculture and sustainable energy and move their solutions closer to commercialisation.

A meaningful step for NorFalk. 🚀 We've raised funding to accelerate bringing our bio-based chemistry to market, taking our total funding past 5 million euros since we started in 2022. Our first products already match conventional performance benchmarks while being among the mildest ingredients tested, all without petrochemicals, palm oil, or palm kernel oil. One principle has guided us from day one: no new product gets developed unless a customer has actually asked for it. That approach has produced several signed LOIs, more than 100 samples delivered worldwide, a first commercial agreement with an international personal care brand, and a completed tech transfer to a manufacturing partner for pilot production. We're grateful for the investment from Delphinus Venture Capital and a consortium of Business Angels: Glenn Petersen, Jan Sterobo, Kraen Oestergaard Nielsen, Jens Lorens Poulsen, Lasse Bolander, Morten Trolle & Mark Leader, who believed in this early, and for financial support from the BioInnovation Institute (BII) through the Upscalator programme, where we were the first company accepted. 🫱🏼‍🫲🏽 "As a chemical and biotech engineer, you have an obligation to make the world a better place. You have the background and the knowledge. It is the bare minimum," says Kasper Olesen Falkenberg, our CEO and co-founder. The real work starts now. 👨‍🔬 | 25 comments on LinkedIn

Oasicare creates medical devices to help prevent severe perineal tears and OASI during vaginal childbirth.